Best PRP therapy for knee osteoarthritis: An analysis of clinical efficacy and treatment protocols

Platelet-rich plasma (PRP) therapy has emerged as a prominent orthobiologic intervention for patients suffering from knee osteoarthritis (OA) who seek alternatives to traditional non-operative standard-of-care therapies such as analgesics, weight management, and corticosteroid injections 1. By isolating and concentrating a patient’s own platelets, clinicians aim to introduce mediators into the joint space that potentially suppress inflammatory cytokines and support joint function 1, 5. As the practice gains traction, standardized guidance from organizations like the American Academy of Physical Medicine and Rehabilitation (AAPM&R) has become essential for defining responsible application parameters 1.

Clinical Efficacy and Comparative Performance

Recent research indicates that PRP provides superior patient-reported pain and function outcomes compared to hyaluronic acid (HA), corticosteroids (CS), or saline placebos through a six-month follow-up period 2. Meta-analyses involving nearly 5,000 patients have demonstrated that these benefits often persist for up to twelve months when compared directly against HA and corticosteroids 2. In studies specifically targeting late-stage knee osteoarthritis, PRP has shown sustained reductions in visual analog scale (VAS) pain scores and improvements in WOMAC functional scores compared to patients receiving only NSAIDs or corticosteroid injections 10.

Understanding Leukocyte Variations in PRP Formulations

A critical consideration in PRP preparation is the presence or absence of leukocytes. Clinical investigations compare leukocyte-rich PRP (L-PRP) and leukocyte-poor PRP (LP-PRP) to determine optimal therapeutic effects 3. While both formulations have demonstrated superiority over placebo and hyaluronic acid in improving WOMAC functional scores over 6 to 12 months, network meta-analyses suggest that LP-PRP may be the most effective, particularly when balancing efficacy with the reduction of post-injection inflammatory flare-ups 3, 8. Choosing between these variants is often based on clinical assessment of the joint environment and the desired inflammatory modulation 3.

Technical Factors Influencing Treatment Outcomes

The methodology used to prepare PRP can significantly influence its potential performance. Research into blood-draw volumes suggests that a total draw volume of 40 mL or greater is associated with more robust improvements in six-month functional outcomes and twelve-month pain relief compared to lower-volume protocols 2. Furthermore, comparisons between single-centrifugation and double-centrifugation techniques continue to be studied to determine the most consistent platelet concentrations 7. Standardization remains a challenge, as experts note that variability in injection techniques and dosage contributes to the current lack of a universally accepted definitive standard of care 4, 5.

Combination Therapies and Emerging Strategies

Researchers are increasingly exploring the efficacy of combining PRP with other agents, such as non-crosslinked hyaluronic acid, to potentially enhance clinical benefit. A multicenter, randomized controlled trial recently compared a PRP-HA combination against crosslinked HA monotherapy, finding that the combination demonstrated significant improvements in pain scores at six months 9. Despite these findings, some network meta-analyses suggest that the additional benefit of combining PRP with other substances compared to PRP monotherapy remains a subject of ongoing clinical debate, necessitating further large-scale research 6.

Patient Selection and Safety Considerations

The efficacy of PRP therapy is often correlated with the stage of osteoarthritis and the age of the patient. Meta-analyses indicate that benefits are particularly significant in patients under 60 years of age and in those with primary rather than post-traumatic OA 8. While PRP is generally considered safe, it is associated with transient adverse events, most commonly localized injection-site reactions, pain, and stiffness that typically resolve within a few days 8, 9. For patients with severe, end-stage (Grade IV) osteoarthritis, the clinical utility of PRP is often limited, and joint replacement surgery remains the established gold standard 5.

Regulatory and Financial Context

In the United States, PRP therapy is generally categorized as an elective, out-of-pocket medical expense because many private insurance providers consider the treatment investigational 5, 6. Because there is no standardized, globally recognized dosing or preparation method, clinical guidance remains focused on individualized care based on existing literature rather than broad medical consensus 4. Prospective patients are encouraged to discuss the specific preparation method, the leukocyte profile of the proposed injection, and the expected realistic outcomes based on their specific radiographic stage of knee degeneration with their healthcare provider 1.

Sources

1. AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis (doi.org/10.1002/pmrj.70144)
2. Autologous platelet-rich plasma versus hyaluronic acid, corticosteroids or saline for knee osteoarthritis (doi.org/10.1007/s00264-026-06782-7)
3. Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis (doi.org/10.1186/s13018-026-06689-4)
4. AAOS Quality Programs: Osteoarthritis of the Knee (aaos.org)
5. PRP injection for knee osteoarthritis: Does it work? (Harvard Health)
6. Comparative efficacy of platelet-rich plasma monotherapy versus combination therapies for knee osteoarthritis (doi.org/10.1186/s13018-026-07042-5)
7. A comparative study of the efficacy of single and double centrifuged platelet-rich plasma (doi.org/10.1186/s42358-026-00518-2)
8. Investigating the therapeutic impact of platelet-rich plasma on knee, hip, and traumatic osteoarthritis (doi.org/10.1186/s12891-026-09486-6)
9. Efficacy and safety of a combination of platelet-rich plasma with non-crosslinked hyaluronic acid (doi.org/10.1186/s12891-026-09625-z)
10. Intra-articular platelet-rich plasma demonstrates superior clinical and serum biomarker outcomes (doi.org/10.1186/s13018-026-07013-w)